WellCare Health Plans
The managed care services company is scheduled to report fourth-quarter earnings on Feb. 15. Analysts, on average, expect profit of $1.17 a share on revenue of $1.59 billion in revenue.Bank of America Merrill Lynch analysts upgraded the stock on Jan. 20 to a buy from a neutral. "Our view is that selling Medicaid and Medicare is evolving into a differentiated capability for WCG now that it covers more duals to cross-sell," Bank of America Merrill Lynch analysts wrote in the report. "The combination of better than expected revenues and strong margins returns yields a favorable risk/reward profile." Shares of WellCare hit a 52-week high on Wednesday of $62.80. The stock's 52-week low of $30.53 was set on Feb. 3. WellCare gets a B grade from TheStreet Ratings with a $73.84 price target. The stock has risen 18.11% year to date.
Alexion Pharmaceuticals The biopharmaceutical company is scheduled to report fourth-quarter earnings on Feb. 9. Analysts, on average, expect profit of 34 cents a share on revenue of $220.8 million. "We believe ALXN can achieve strong top-line growth relative to biotech peers, based on Soliris' market potential in PNH and other indications," Oppenheimer analysts wrote in a Jan. 23 report. "Near term, we expect ALXN to continue to drive robust Soliris sales growth in PNH through strong commercial execution and geographic expansion." Shares of Alexion Pharmaceuticals hit a 52-week high of $78.05 on Wednesday. The stock's 52-week low of $41.65 was on Feb. 4. TheStreet Ratings gives Alexion a B+ grade with a $98.37 price target. The stock has increased 8.24% year to date.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV